Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients

Current Opinion in Oncology

Volumn 18, Issue 3, 2006, Pages 266-270

  De Castro Jr , Gilberto ^a   Honda Federico, Miriam Hatsue ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amifostine; Head and neck cancer; Radiation therapy; Xerostomia

Indexed keywords

AMIFOSTINE; CEVIMELINE; PILOCARPINE; PLACEBO; TOOTHPASTE;

ACUPUNCTURE; AGEUSIA; CANCER INHIBITION; CLINICAL TRIAL; DENTAL CARIES; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; INTENSITY MODULATED RADIATION THERAPY; MASTICATION; MOUTH PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

AMIFOSTINE; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; CYTOPLASMIC GRANULES; FREE RADICAL SCAVENGERS; HEAD AND NECK NEOPLASMS; HUMANS; LIPID PEROXIDATION; PARASYMPATHOMIMETICS; PILOCARPINE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RADIOTHERAPY, INTENSITY-MODULATED; SALIVARY GLANDS; XEROSTOMIA;

EID: 33646713644     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000219256.37843.83     Document Type: Review

References (44)

1. Sullivan CA, Haddad RI, Tishler RB, et al. Chemoradiation-induced cell loss in human submandibular glands. Laryngoscope 2005; 115:958-964.
2. Braam PM, Roesnik JM, Moerland MA, et al. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62:659-664.
3. Roesink JM, Schipper M, Busschers W, et al. A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: Implications for future trials. Int J Radiat Oncol Biol Phys 2005; 63:1006-1009.
4. Andreassen CN, Grau C, Lindegaard JC. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 2003; 13:62-72.
5. Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 2005; 63:985-990. This phase III study demonstrated that amifostine reduced the severity and duration of xerostomia 2 years after radiotherapy in head and neck cancer patients, without compromising locoregional control rates, progression-free survival or overall survival.
6. Buentzel J, Micke O, Adamietz IA, et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 2006; 64:684-691. In this phase III study, amifostine reduced neither acute xerostomia and mucositis, nor late xerostomia. Locoregional control, progression-free survival and overall survival were not different between treatment arms.
7. Rades D, Fehlauer F, Bajrovic A, et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 2004; 70:261-264.
8. Snyder-Dougherty L, Sherman E, Riordan D, et al. Cost effectiveness of amifostine for prevention of radiation-induced xerostomia [abstract]. J Clin Oncol 2005; 23 (16S):506.
9. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003; 4:378-381.
10. Leung SF, Teo P, Zee B, et al. Subcutaneous amifostine for reduction of radiation xerostomia in nasopharynx cancer: a prospective randomised study. J Clin Oncol 2005; 23 (16S):739.
11. Haddad R, Wirth L, Costello R, et al. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol 2003; 30 (6 Suppl 18):84-88.
12. Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol 2002; 29 (6 Suppl 19):80-83. Erratum in Semin Oncol 2003; 30:417.
13. Bardet E, Martin L, Calais G, et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 2002; 29 (6 Suppl 19):57-60.
14. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000; 18:2226-2233.
15. Braaksma MM, Wijers OB, van Sornsen de Koste JR, et al. Optimisation of conformal radiation therapy by intensity modulation: cancer of the larynx and salivary gland function. Radiother Oncol 2003; 66:291-302.
16. Chao KS, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001; 61:275-280.
17. Seikaly H, Jha N, McGaw T, et al. Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope 2001; 111:347-352.
18. Eisbruch A, Ten Haken RK, Kim HM, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 45:577-587.
19. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001; 49:907-916.
20. Bussels B, Maes A, Hermans R, et al. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer. Radiother Oncol 2004; 72:119-127.
21. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:695-704.
22. Amosson CM, Teh BS, Van TJ, et al. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. Int J Radiat Oncol Biol Phys 2003; 56:136-144.
23. Saarilahti K, Kouri M, Collan J, et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 2005; 74:251-258.
24. Parliament MB, Scrimger RA, Anderson SG, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity-modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 58:663-673. Oral health-related quality of life was shown to be preserved one year after IMRT as assessed by the University of Washington quality of life questionnaire.
25. Lin A, Kim HM, Terrell JE, et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2003; 57:61-70.
26. Jabbari S, Kim HM, Feng M, et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys 2005; 63:725-731.
27. Rudat V, Münter M, Rades D, et al. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy [abstract]. J Clin Oncol 2005; 23 (16S):500.
28. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993; 329:390-395.
29. LeVeque FG, Montgomery M, Potter D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993; 11:1124-1131.
30. Scarantino CW, LeVeque FG, Scott CB, et al. A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis associated with curative radiation therapy in head and neck cancer patients. RTOG 9709 [abstract] Proc Am Soc Clin Oncol 2001; 20:225.
31. Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer-RTOG 97-09. Int J Radiat Oncol Biol Phys 2003; 56:832-836.
32. Ringash J, Warde P, Lockwood G, et al. Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys 2005; 61:1403-1407.
33. Momm F, Volegova-Neher NJ, Schulte-Monting J, et al. Different saliva substitutes for treatment of xerostomia following radiotherapy a prospective crossover study. Strahlenther Onkol 2005; 181:231-236.
34. Warde P, Kroll B, O'Sullivan B, et al. A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 2000; 8:203-208.
35. Chambers MS, Posner MR, Jones CU, et al. Two phase III clinical studies of cevimeline for post-radiation xerostomia in patients with head and neck cancer [abstract]. J Clin Oncol 2005; 23 (16S):500.
36. Wong RKW, Jones GW, Sagar SM, et al. A phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57:472-480.
37. Thorstad WL, Chao KS, Haughey B. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol 2004; 31 (6 Suppl 18):8-12.
38. Rosenthal DI, Chambers MS, Weber RS, et al. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol 2004; 31 (6 Suppl 18):25-28.
39. Seikaly H, Jha N, Harris JR, et al. Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg 2004; 130:956-961. Submandibular gland transfer (Seikaly-Jha procedure) prevented xerostomia in most of patients (83%) submitted to this procedure before radiotherapy.
40. Rieger J, Seikaly H, Jha N, et al. Submandibular gland transfer for prevention of xerostomia after radiation therapy: swallowing outcomes. Arch Otolaryngol Head Neck Surg 2005; 131:140-145. The Seikaly-Jha procedure for submandibulary glands promoted more time-efficient swallowing behaviors in patients submitted to this procedure before radiotherapy.
41. Giri U, Ashorn CL, Ramdas L, et al. Molecular signatures associated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgery and radiation. Int J Radiat Oncol Biol Phys 2006; 64:670-677.
42. Eriksen JG, Alsner J, Steiniche T, et al. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. Radiother Oncol 2005; 76:135-142. Mutations in TP53 may be associated with HNSCCs that benefit from a reduced overall treatment time of radiotherapy, despite that these TP53-mutations were not related to local control or survival.
43. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23:5560-5567. Better locoregional tumor control from continuous hyperfractionated accelerated radiotherapy was seen in HNC patients with higher EGFR expression, suggesting role for the EGFR receptor in determining the proliferative cellular response to fractionated radiotherapy.
44. Overgaard J, Kriksen JG, Nordsmark M, et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005; 6:757-764. High plasma concentrations of osteopontin were associated with poor outcomes after radiotherapy in HNC patients, but could be improved by use of nimorazole, suggesting that it could predict clinically relevant hypoxia and identify those patients who would benefit from modification of hypoxia during radiation therapy.